Immunotherapy News and Research

Latest Immunotherapy News and Research

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

Generex Biotechnology Corporation today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 Dec 2011

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.

14 Dec 2011

ImmusanT secures $20M in Series A financing

ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease.

14 Dec 2011

Scientists create antigenic myeloma peptide 'cocktail'

Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.

13 Dec 2011

Technique expands scarce resources used for cord blood transplant procedure

A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.

12 Dec 2011

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

12 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

Milk powder outperforms lower-dose therapy for treatment of food allergies

A small study by researchers at the Johns Hopkins Children's Center and Duke University shows that eating higher doses of milk protein in the form of dry powder substantially outperforms lower-dose therapy — a few drops of liquid milk extract under the tongue — for treatment of food allergies.

7 Dec 2011

Body's surveillance for cancer causing damage and response to allergies share common pathway

CANCER RESEARCH UK scientists have found that the body's surveillance for cancer causing damage and its response to allergies share a common pathway, according to research published in Science on Thursday.

1 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Counterparts of memory cells ward off microbial foes

The immune system possesses a type of cell that can be activated by tissues within the body to remind the immune system not to attack our own molecules, cells and organs, UCSF researchers have discovered.

29 Nov 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.

23 Nov 2011

Arginine may reactivate T-cells in patients with glioblastoma

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis.

22 Nov 2011

Coffee may protect against womb cancer: Study

For the study the researchers looked at coffee consumption and endometrial cancer risk in more than 67,000 women aged between 34 and 59 enrolled in the long-running Nurses' Health Study. The researchers found that women who took more than four cups of coffee a day over a 26-year period were 25 percent less likely to get the cancer.

22 Nov 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

ImmusanT secures $20M in Series A financing

Scientists create antigenic myeloma peptide 'cocktail'

Technique expands scarce resources used for cord blood transplant procedure

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Milk powder outperforms lower-dose therapy for treatment of food allergies

Body's surveillance for cancer causing damage and response to allergies share common pathway

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Counterparts of memory cells ward off microbial foes

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Arginine may reactivate T-cells in patients with glioblastoma

Coffee may protect against womb cancer: Study

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: The Ultimate Guide to Successful Immunofluorescence eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in